drugset

drugset / Trial / NCT01678092

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

NCT01678092 ↗

Phase 1 Completed 8 enrolled Stanford University

RandomizedSingle-groupTriple-blindTreatment

Summary

A phase 1 single center study in which omalizumab is dosed normally (according to the product insert) in subjects with atopic dermatitis.

Timeline

Start: 2004-05
Primary completion: 2006-12
Completion: 2006-12

Publications

Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89-93. doi: 10.1159/000350486. Epub 2013 Jun 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omalizumab	Monoclonal antibody	—	Subcutaneous

Indications